S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
NASDAQ:POAI

Predictive Oncology (POAI) Stock Price, News & Analysis

$3.42
-0.09 (-2.56%)
(As of 02/23/2024 ET)
Today's Range
$3.40
$3.60
50-Day Range
$2.72
$3.72
52-Week Range
$2.47
$13.88
Volume
16,392 shs
Average Volume
14,504 shs
Market Capitalization
$13.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

POAI stock logo

About Predictive Oncology Stock (NASDAQ:POAI)

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

POAI Stock Price History

POAI Stock News Headlines

Predictive tests: How accurate?
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Predictive Oncology Inc POAI
3 AI Stocks Worth Buying Now for Multibagger Returns
Predictive Oncology moves company headquarters to Pittsburgh
See More Headlines
Receive POAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2021
Today
2/25/2024
Next Earnings (Estimated)
3/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Current Symbol
NASDAQ:POAI
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Net Income
$-25,740,000.00
Net Margins
-1,018.52%
Pretax Margin
-1,018.52%

Debt

Sales & Book Value

Annual Sales
$1.51 million
Book Value
$5.53 per share

Miscellaneous

Free Float
3,923,000
Market Cap
$13.89 million
Optionable
Not Optionable
Beta
1.28
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Raymond F. Vennare (Age 72)
    CEO & Chairman
    Comp: $581.58k
  • Mr. Joshua Blacher M.B.A. (Age 51)
    Interim Chief Financial Officer
  • Ms. Theresa Ferguson
    Senior Director of Marketing
  • Dr. Pamela Bush M.B.A. (Age 50)
    Ph.D., Chief Business Officer
  • Dr. Lawrence J. DeLucas D.Sc
    O.D, Ph.D., Senior Vice President of Biologics
  • Dr. Arlette H. Uihlein FCAP
    M.D., Senior VP of Translational Medicine & Drug Discovery and Medical Director














POAI Stock Analysis - Frequently Asked Questions

How have POAI shares performed in 2024?

Predictive Oncology's stock was trading at $3.29 at the start of the year. Since then, POAI shares have increased by 4.0% and is now trading at $3.42.
View the best growth stocks for 2024 here
.

Are investors shorting Predictive Oncology?

Predictive Oncology saw a decrease in short interest in January. As of January 31st, there was short interest totaling 32,200 shares, a decrease of 8.3% from the January 15th total of 35,100 shares. Based on an average daily trading volume, of 17,400 shares, the short-interest ratio is presently 1.9 days. Currently, 0.8% of the shares of the company are sold short.
View Predictive Oncology's Short Interest
.

When is Predictive Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024.
View our POAI earnings forecast
.

How were Predictive Oncology's earnings last quarter?

Predictive Oncology Inc. (NASDAQ:POAI) released its quarterly earnings data on Wednesday, August, 11th. The medical instruments supplier reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.60) by $0.60. The medical instruments supplier earned $0.35 million during the quarter, compared to analyst estimates of $0.80 million. Predictive Oncology had a negative net margin of 1,018.52% and a negative trailing twelve-month return on equity of 109.76%.

When did Predictive Oncology's stock split?

Shares of Predictive Oncology reverse split on the morning of Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Predictive Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Platforms (RIOT), AcelRx Pharmaceuticals (ACRX), Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE).

Who are Predictive Oncology's major shareholders?

Predictive Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Carnegie Mellon University (0.26%). Insiders that own company stock include Charles Lee Sr Nuzum Sr, Daniel E Handley, J Melville Engle, Raymond F Vennare and Robert L Myers.
View institutional ownership trends
.

How do I buy shares of Predictive Oncology?

Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:POAI) was last updated on 2/25/2024 by MarketBeat.com Staff